$30M series A will propel Tranquis to the clinic with its neuroinflammation candidate

By Elizabeth S. Eaton, Staff Writer | Jul 10, 2020 | 7:58 PM GMT

Stanford spinout Tranquis is the latest biotech looking to put the neuroinflammation theory to the test, raising $30 million Thursday in a series A to bring its first neurodegenerative disease candidate to the clinic next year.

Remiges Ventures and SR

Read the full 405 word article

How to gain access

Continue reading with a
two-week free trial.